For instance, decreased ABH5 expression levels are an independent prognostic factor of worse survival in patients with hepatocellular carcinoma [167] and correlate with a worse prognosis in patients with bladder cancer [168]. Here, ALKBH5 is linked to urinary bladder cancer.